Conferences

Nouscom Poster presentation at ASCO 2022, reporting the full Phase 1 Data of NOUS-209, an ‘off-theshelf’ Neoantigen Cancer Immunotherapy for the Treatment of dMMR/MSI-H Solid Tumors. NOUS-209 in [...]

Nouscom Poster presentation at CIMT 2022, reporting on the generation of a Modified Vaccinia Ankara (MVA) virus encoding IL-12 as a novel approach of “Vector Aided Microenvironment Programing: [...]

Nouscom Poster presentation at AACR 2022, reporting on new translational Phase 1 data illustrating how NOUS-209, an off-the-shelf neoantigen immunotherapy, with pembrolizumab for treatment of [...]

Nouscom Poster presentation at SITC 2021, reporting interim Phase 1 results on Nous-209, an off-the-shelf immunotherapy, with pembrolizumab, for the treatment of tumors with a deficiency in [...]

Nouscom Poster presentation at ESMO 2021, reporting the first clinical dataset from the Phase 1 trial of NOUS-209, an off-the-shelf cancer vaccine based on shared neoantigens, in combination with [...]